In the CCH phase, prolonged low levels of CCL11 are detrimental to the prognosis of patients with cerebral ischemia; CX3CL1, XCL-1 and CCL2/MCP-1 exert neuroprotective effects. Here, XCL1 is linked to brain ischemia.